Citi maintains buy on CSL after mammoth takeover
MELBOURNE: Citi analysts have maintained their ‘buy’ rating on biotech giant CSL, noting that the
MELBOURNE: Citi analysts have maintained their ‘buy’ rating on biotech giant CSL, noting that the